Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer - Top-Institutions - MDSpire

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

  • By

  • Bingbing Li

  • Yuning Ren

  • Xiaoling Zhang

  • April 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Thoracic Oncology
    • Immunotherapy Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Immuno-oncology
    • Translational Cancer Research

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Medical Oncology
    • Cancer Immunotherapy
    • Clinical Trials

  • #4

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Cancer Biology

  • #5

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Clinical and Translational Research

Original Source(s)

Challenges and Utilization of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer

  • by Bingbing Li, Yuning Ren, Xiaoling Zhang

  • April 20, 2026

Related Content

Editorial: The role of circular RNAs and MicroRNAs in non-small cell lung cancer: from mechanisms to therapeutic potential

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression